Molecular diagnostics is poised to transform health care in the coming decade.
The molecular diagnostic industry is quickly evolving because of many factors including success with the companion diagnostic model, the rapid advance of gene sequencing and other detection technologies, the Affordable Care Act, and the Supreme Court’s reworking of the boundaries of patentable subject matter. As a result, companies in this space must learn to navigate a quickly evolving industry and drastically changed legal framework if they are to be successful in protecting their innovations and investments.